Core Portfolio

CRO/CMO

  • WUXI APPTEC

    Leading global integrated life science services platform

  • WUXI BIOLOGICS

    A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing

Biopharma

  • ATEA PHARMACEUTICALS (IPO ON U.S. NASDAQ ON OCT 30, 2020)

    Developing world’s potentially new best-in-class anti-viral drugs for COVID-19, HCV and RSV

  • HUA MEDICINE (IPO ON HKEX ON SEP 14, 2018)

    Global first-in-class GKA-based drug to treat Type II diabetes

  • TESARO (EXITED - ACQUISITION BY GSK IN 2018)

    World's new best-in-class drug for ovarian cancer

  • VIFOR PHARMA (EXITED)

    Vifor Pharma Group, formerly Galenica Group, is a global specialty pharmaceuticals company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions.

  • GOLDFINCH BIO

    Developing genomics-based precision medicine for kidney disease treatments.

  • NUVATION BIO (ANNOUNCED BUSINESS COMBINATION AGREEMENT WITH PANACEA ACQUISITION (NYSE:PANA / SPAC) ON OCT 21, 2020)*

    A biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology (*Combination subject to customary closing conditions and completion of the transaction)

  • CEREVEL THERAPEUTICS (TRADING OF COMMON STOCK AND WARRANTS COMMENCED ON U.S. NASDAQ ON OCT 28, 2020 UNDER TICKER SYMBOLS “CERE” AND “CEREW” AFTER COMPLETION OF BUSINESS COMBINATION WITH ARYA SCIENCES ACQUISITION CORP II)

    A clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies

Medtech

  • MEDTECH (ACQUIRED BY ZIMMER BIOMET)

    Global leader in brain and spine surgical robots

  • SHOCKWAVE (IPO ON U.S. NASDAQ ON MAR 7, 2019)

    World-leading device for cardiovascular diseases

  • NXTHERA (ACQUIRED BY BOSTON SCIENTIFIC)

    World-leading innovative device to treat urological disorders

  • SONENDO

    Global leader in innovative dentistry (root canal treatment) (*Invested and managed by the ABG Team through an affiliate)

  • QUANTUM SURGICAL

    Global leader in innovative surgical robots for interventional oncology

  • PULMONX (IPO ON U.S. NASDAQ ON OCT 1, 2020)

    Global leader in minimally invasive treatment for interventional pulmonology

  • IMPERATIVE CARE

    World-leading innovative device for stroke treatment

  • VENCLOSE

    World-leading device for venous reflux disease

  • Mainstay

    Mainstay develops and commercializes ReActiv8, an innovative implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain (CLBP)

  • CMR

    A global surgical robotic company dedicated to transforming surgery with its Versius system

Life Science Technologies / Tools

  • GRAIL (ANNOUNCED ACQUISITION BY ILLUMINA ON SEP 22, 2020)

    GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. (*Acquisition subject to customary closing conditions and completion of the transaction)

  • RAPID MICRO BIOSYSTEMS (IPO ON U.S. NASDAQ ON JUL 15, 2021)

    Based in Boston, Massachusetts, Rapid Micro Biosystems is the first provider of the fully automated, high-volume and secure Microbial Quality Control (MQC) solution for pharmaceutical manufacturing (primary focus), food and beverage safety, personal care manufacturing, environmental water sector, industrial processing and diagnostics.

CRO/CMO

  • Wuxi Apptec

    WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations.

  • Wuxi Biologics

    A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing

Biopharma

  • LUOXIN PHARMACEUTICAL GROUP (LISTING ON A-SHARE IN 2019)

    Shandong Luoxin Pharmaceutical Group is a large-scale pharmaceutical enterprise group integrating drug research and development, manufacturing, trading with medical treatment and health services.

  • HUA MEDICINE (IPO ON HKEX ON SEP 14, 2018)

    Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders.

Medtech

  • MEGA

    Mega Dental is a leading dental product company in China that manufactures and sells restorative and prosthetics dental products, including dentures, veneers, crowns and bridges.

  • LIFETECH SCIENTIFIC

    LifeTech Scientific Corporation (Stock Code: 1302.HK) is the leading supplier of minimally invasive interventional medical devices to treat cardiovascular and peripheral vascular diseases. (*Invested and managed by the ABG Team through an affiliate)

Digital Health

  • LINKDOC

    LinkDoc Technology Limited is a leading oncology big data company, based in Beijing, China. The company has established partnerships with more than 200 of China's top oncology hospitals for the collection, collation and analysis of cancer patients' medical records and clinical data. To-date the company has built a cloud-based repository of more than 400,000 oncology medical records covering all types of cancers.

Biopharma

  • ATEA PHARMACEUTICALS (IPO ON U.S. NASDAQ ON OCT 30, 2020)

    Developing world’s potentially new best-in-class anti-viral drugs for COVID-19, HCV and RSV

  • TESARO (EXITED - ACQUISITION BY GSK IN 2018)

    World's new best-in-class drug for ovarian cancer

  • SORRENTO

    Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento’s lead products are multiple late-stage biosimilar and biobetter antibodies as well as clinical CAR-T therapies targeting solid tumors.

  • GOLDFINCH BIO

    Developing genomics-based precision medicine for kidney disease treatments.

  • NUVATION BIO (ANNOUNCED BUSINESS COMBINATION AGREEMENT WITH PANACEA ACQUISITION (NYSE:PANA / SPAC) ON OCT 21, 2020)*

    A biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology (*Combination subject to customary closing conditions and completion of the transaction)

  • CEREVEL THERAPEUTICS (TRADING OF COMMON STOCK AND WARRANTS COMMENCED ON U.S. NASDAQ ON OCT 28, 2020 UNDER TICKER SYMBOLS “CERE” AND “CEREW” AFTER COMPLETION OF BUSINESS COMBINATION WITH ARYA SCIENCES ACQUISITION CORP II)

    A clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies

Medtech

  • SHOCKWAVE (IPO ON U.S. NASDAQ ON MAR 7, 2019)

    Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease, creating new opportunities for patients and physicians by effectively targeting calcified plaque.

  • SONENDO

    Sonendo, Inc. provides root canal therapy services for endodontic problems to patients. ( *Managed by ABG's affiliate)

  • AXONICS MODULATION (IPO ON U.S. NASDAQ ON OCT 31, 2018)

    Axonics Modulation (NASDAQ:AXNX) is a medtech company focused on the development, and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions. SNM therapy is primarily used to treat patients with overactive bladder (“OAB”), fecal incontinence (“FI”) and urinary retention (“UR”). Axonics currently has marketing approvals in Europe, Canada, and Australia for OAB, FI, and UR.

  • VAPOTHERM (IPO ON U.S. NASDAQ ON NOV 14, 2018)

    Innovative respiratory support device - its proprietary Hi-VNI Technology delivers noninvasive ventilatory support to patients through a comfortable small-bore nasal interface

  • PULMONX (IPO ON U.S. NASDAQ ON OCT 1, 2020)

    Pulmonx is a medtech company focused on developing life-changing technologies that improve the lives of patients suffering from COPD. Its innovative product, Zephyr Valve, is the first minimally-invasive device approved by the US FDA for treating patients with severe emphysema.

  • IMPERATIVE CARE

    Based in Campbell, California, Imperative Care is speeding new answers to stroke by developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care.

  • VENCLOSE

    Venclose is a Silicon Valley medical technology company developing next-generation solutions for the treatment of venous reflux disease, also known as chronic venous insufficiency (CVI). The VENCLOSE RF Ablation System offers physicians more versatility than earlier generation endovenous radiofrequency ablation technologies.

  • Mainstay

    Mainstay develops and commercializes ReActiv8, an innovative implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain (CLBP)

Life Science Technologies / Tools

  • GRAIL (ANNOUNCED ACQUISITION BY ILLUMINA ON SEP 22, 2020)

    GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. (*Acquisition subject to customary closing conditions and completion of the transaction)

  • RAPID MICRO BIOSYSTEMS (IPO ON U.S. NASDAQ ON JUL 15, 2021)

    Global leader in microbial quality control

Digital Health

  • VIDA HEALTH

    Based in California, US, Vida Health is a world-leading digital polychronic condition management platform offering virtual coaching programmes across chronic disease (e.g. diabetes), mental health (e.g. depression) and lifestyle (e.g. weight loss).

  • MEDAVAIL (LISTED ON U.S. NASDAQ ON NOV 18, 2020 THROUGH REVERSE MERGER)

    A technology-enabled pharmacy organization, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics

  • SYAPSE

    An oncology real-world evidence (RWE) company with the leading footprint within community health systems in the United States.

Biopharma

  • VIFOR PHARMA (EXITED)

    Vifor Pharma Group, formerly Galenica Group, is a global specialty pharmaceuticals company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions.

  • ITAMAR MEDICAL

    A medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders.

Medtech

  • QUANTUM SURGICAL

    Founded in 2017, Quantum Surgical is a next-generation surgical robotics start-up founded by Bertin Nahum, a serial entrepreneur and founder of Medtech SA. The Company is building next-generation smart tools for minimally invasive therapies, beginning with interventional oncology.

  • MAVRIK

    A company with proprietary technologies and products for automated in-office teeth whitening with unparalleled efficiency and outcomes, and gum protection and treatment.

  • CMR

    A global surgical robotic company dedicated to transforming surgery with its Versius system

The portfolio companies (“Portfolio Companies”) listed above in “Core Portfolio” were selected by Ally Bridge Group (“ABG”) based on objective, non-performance based criteria in order to illustrate ABG’s investment process and/or market outlook. The Portfolio Companies were not chosen to demonstrate the profitability of ABG’s investment portfolio or the performance of any other investments in ABG’s investment portfolio. The Portfolio Companies do not represent all of the securities or companies purchased, held, sold, or recommended by ABG. The reader should not assume that ABG’s investment in the Portfolio Companies was or will prove to be profitable, or that the investment recommendations or decisions that ABG makes in the future will be profitable or will equal the investment performance of the Portfolio Companies.